Download PDF
Klin Monbl Augenheilkd 2003; 220(10): 654-668
DOI: 10.1055/s-2003-43131
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Möglichkeiten und Grenzen der photodynamischen Therapie - Eine Übersicht

The Potential and the Limits of Photodynamic Therapy - A ReviewMichael  Stur1
  • 1Univ.-Klinik für Augenheilkunde und Optometrie, Allgemeines Krankenhaus der Stadt Wien
Der Autor hat kein finanzielles Interesse an einem der in der Publikation erwähnten Produkte
Further Information

Publication History

Eingegangen: 30. Juni 2003

Angenommen: 14. August 2003

Publication Date:
24 October 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund: Das Spektrum der Behandlungsmöglichkeiten choroidaler Neovaskularisationen hat durch die Einführung der photodynamischen Therapie eine wesentliche Bereicherung erfahren. Der umfangreiche technische und finanzielle Aufwand, der mit dieser Methode verbunden ist, erfordert aber einen gezielten und konsequenten Einsatz, um einerseits entsprechende Behandlungserfolge zu erzielen und andererseits die Grenzen der vorhandenen Ressourcen nicht zu überschreiten. Dieser gezielte Einsatz ist nur dann möglich, wenn die Grundlagen der Diagnose, der Indikationsstellung, der Behandlung und der Nachbetreuung ausreichend bekannt sind und entsprechend angewendet werden. Material, Methoden und Resultate: Die Standardtherapie, bisher darüber publizierte Studien und klinische Erfahrungsberichte werden im Überblick präsentiert und kritisch kommentiert. Schlussfolgerungen: Die photodynamische Therapie mit Verteporfin kann zwar in vielen Fällen einen massiven Visusverlust verhindern, die Ergebnisse sind aber je nach Grundkrankheit sehr unterschiedlich. Eine photodynamische Therapie sollte daher nur nach strenger Indikationsstellung erfolgen. Kombinationen mit anderen medikamentösen Therapien und Anpassungen der Behandlungsparameter werden vielleicht in Zukunft die Behandlungsergebnisse verbessern.

Abstract

Background: The spectrum of possible treatments for choroidal neovascularisation has been considerably increased with the introduction of photodynamic therapy. On the other hand the technical complexity and high cost associated with this new method require a pinpointed and dedicated application to achieve not only treatment benefits for the patients, but also not to exceed the available resources. This focussed application of the new treatment method can only be performed if the basics of diagnosis, indication, treatment and follow-up care are sufficiently known and used. Material, methods and results: The standard treatment protocol, the results of published clinical trials as well as many published clinical observations are presented and discussed. Conclusions: Photodynamic therapy with verteporfin can prevent massive loss of vision in many cases of subfoveal choroidal neovascularisation, but the treatment outcome depends on many factors, the most important being the underlying disease process. Hence, indication for photodynamic therapy should adhere to the published treatment guidelines. In the future, additional medications or alterations of the treatment protocol might improve treatment outcome.

Schlüsselwörter

Altersbedingte Makuladegeneration - Chorioretinopathia centralis serosa - choroidale Neovaskularisation - Aderhauthämangiom - Fluoreszenzangiographie - optische Kohärenztomographie - photodynamische Therapie - Verteporfin

Key words

Age-related macular degeneration - central serous chorioretinopathy - choroidal neovascularisation - choroidal haemangioma - fluorescein angiography - optical coherence tomography - photodynamic therapy - verteporfin

Literatur

  • 1 The Moorfields Macular Study Group . Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation.  Br J Ophthalmol. 1982;  66 745-753
    PubMedGoogle Scholar
  • 2 The Macular Photocoagulation Study Group . Age-related macular degeneration.  Am J Ophthalmol. 1984;  98 376-377
    PubMedGoogle Scholar
  • 3 Macular Photocoagulation Study Group . Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy.  Arch Ophthalmol. 1986;  104 503-512
    Google Scholar
  • 4 Macular Photocoagulation Study Group . Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration.  Arch Ophthalmol. 1990;  108 825-831
    PubMedGoogle Scholar
  • 5 Macular Photocoagulation Study Group . Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial.  Arch Ophthalmol. 1991;  109 1220-1231
    PubMedGoogle Scholar
  • 6 Macular Photocoagulation Study Group . Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials (published erratum appears in Arch Ophthalmol 1992 Jun; 110 [6]: 761).  Arch Ophthalmol. 1991;  109 1109-1114
    PubMedGoogle Scholar
  • 7 Pharmacological Therapy for Macular Degeneration Study Group . Interferon α-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial.  Arch Ophthalmol. 1997;  115 865-872
    PubMedGoogle Scholar
  • 8 RAD Study Group . A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Radiation Therapy for Age-related Macular Degeneration.  Ophthalmology. 1999;  106 2239-2247
    CrossrefPubMedGoogle Scholar
  • 9 TAP Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.  Arch Ophthalmol. 1999;  117 1329-1345
    CrossrefPubMedGoogle Scholar
  • 10 Submacular Surgery Trial Study Group . Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1.  Am J Ophthalmol. 2000;  130 387-407
    CrossrefPubMedGoogle Scholar
  • 11 Submacular Surgery Trial Study Group . Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: II. Quality of life outcomes submacular surgery trials pilot study report number 2.  Am J Ophthalmol. 2000;  130 408-418
    CrossrefPubMedGoogle Scholar
  • 12 VIP Study Group . Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2.  Am J Ophthalmol. 2001;  131 541-560
    CrossrefPubMedGoogle Scholar
  • 13 VIP Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1.  Ophthalmology. 2001;  108 841-852
    CrossrefPubMedGoogle Scholar
  • 14 Verteporfin Roundtable 2000 and 2001 participants, TAP and VIP Study Group principal investigators . Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.  Retina. 2002;  22 6-18
    PubMedGoogle Scholar
  • 15 Eyetech Study Group . Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.  Retina. 2002;  22 143-152
    PubMedGoogle Scholar
  • 16 VIP Study Group . Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3.  Ophthalmology. 2003;  110 667-673
    CrossrefPubMedGoogle Scholar
  • 17 TAP VIP Study Group . Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report #1. Treatment of age-related macular degeneration with photodynamic therapy (TAP) and verteporfin in photodynamic therapy (VIP) study groups.  Am J Ophthalmol. 2003;  136 407-418
    CrossrefPubMedGoogle Scholar
  • 18 Barbazetto I, Schmidt-Erfurth U. Photodynamic therapy of choroidal hemangioma: two case reports.  Graefes Arch Clin Exp Ophthalmol. 2000;  238 214-221
    CrossrefPubMedGoogle Scholar
  • 19 Benson M T, Callear A, Tsaloumas M, Chhina J, Beatty S. Surgical excision of subfoveal neovascular membranes.  Eye. 1998;  12 768-774
    PubMedGoogle Scholar
  • 20 Blumenkranz M S, Woodburn K W, Qing F, Verdooner S, Kessel D, Miller R. Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy.  Am J Ophthalmol. 2000;  129 353-362
    CrossrefPubMedGoogle Scholar
  • 21 Carrasquillo K G, Ricker J A, Rigas I K, Miller J W, Gragoudas E S, Adamis A P. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.  Invest Ophthalmol Vis Sci. 2003;  44 290-299
    CrossrefPubMedGoogle Scholar
  • 22 D'Amico D J, Goldberg M F, Hudson H, Jerdan J A, Krueger S, Luna S. et al . Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.  Retina. 2003;  23 14-23
    PubMedGoogle Scholar
  • 23 Dantas M A, Slakter J S, Negrao S, Fonseca R A, Kaga T, Yannuzzi L A. Photodynamic therapy with verteporfin in mallatia leventinese.  Ophthalmology. 2002;  109 296-301
    CrossrefPubMedGoogle Scholar
  • 24 Farah M E, Costa R A, Muccioli C, Guia T A, Belfort R. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome.  Am J Ophthalmol. 2002;  134 137-139
    CrossrefPubMedGoogle Scholar
  • 25 Fernandes L H, Freund K B, Yannuzzi L A, Spaide R F, Huang S J, Slakter J S. et al . The nature of focal areas of hyperfluorescence or hot spots imaged with indocyanine green angiography.  Retina. 2002;  22 557-568
    PubMedGoogle Scholar
  • 26 Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.  Semin Oncol. 2002;  29 10-14
    PubMedGoogle Scholar
  • 27 Ferris F D, Fine S L, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy.  Arch Ophthalmol. 1984;  102 1640-1642
    PubMedGoogle Scholar
  • 28 Friedman S M, Margo C E. Choroidal neovascular membranes: reproducibility of angiographic interpretation.  Am J Ophthalmol. 2000;  130 839-841
    CrossrefPubMedGoogle Scholar
  • 29 Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization.  Am J Ophthalmol. 2001;  131 518-520
    CrossrefPubMedGoogle Scholar
  • 30 Haas A, Prettenhofer U, Stur M, Hanselmayer R, Feigl B, Berghold A. et al . Morphologic characteristics of disciform scarring after radiation treatment for age-related macular degeneration.  Ophthalmology. 2000;  107 1358-1363
    CrossrefPubMedGoogle Scholar
  • 31 Hart P M, Chakravarthy U, Mackenzie G, Chisholm I H, Bird A C, Stevenson M R. et al . Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration.  Arch Ophthalmol. 2002;  120 1029-1038
    CrossrefPubMedGoogle Scholar
  • 32 Holz F G, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study).  Ophthalmology. 2003;  110 400-405
    CrossrefPubMedGoogle Scholar
  • 33 Honda M, Sakamoto T, Ishibashi T, Inomata H, Ueno H. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration.  Gene Ther. 2000;  7 978-985
    CrossrefPubMedGoogle Scholar
  • 34 Jurklies B, Anastassiou G, Ortmans S, Schuler A, Schilling H, Schmidt-Erfurth U. et al . Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma.  Br J Ophthalmol. 2003;  87 84-89
    CrossrefPubMedGoogle Scholar
  • 35 Kaiser R S, Berger J W, Williams G A, Tolentino M J, Maguire A M, Alexander J. et al . Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration.  Retina. 2002;  22 683-690
    PubMedGoogle Scholar
  • 36 Kanai M, Obana A, Gohto Y, Nagata S, Miki T, Kaneda K. et al . Long-term effectiveness of photodynamic therapy by using a hydrophilic photosensitizer ATX-S10(Na) against experimental choroidal neovascularization in rats.  Lasers Surg Med. 2000;  26 48-57
    CrossrefPubMedGoogle Scholar
  • 37 Kazi A, Peyman G, Unal M, Khoobehi B, Yoneya S, Mori K. et al . Threshold power levels for NPe6 photodynamic therapy.  Ophthalmic Surg Lasers. 2000;  31 136-142
    PubMedGoogle Scholar
  • 38 Kjeka O, Krohn J. Photodynamic therapy of circumscribed choroidal haemangioma.  Acta Ophthalmol Scand. 2002;  80 557-558
    CrossrefPubMedGoogle Scholar
  • 39 Kramer M, Miller J, Michaud N, Moulton R, Hasan T, Flotte T. et al . Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.  Ophthalmology. 1996;  103 427-438
    PubMedGoogle Scholar
  • 40 Landau I M, Steen B, Seregard S. Photodynamic therapy for circumscribed choroidal haemangioma.  Acta Ophthalmol Scand. 2002;  80 531-536
    CrossrefPubMedGoogle Scholar
  • 41 Lim J I. Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials.  Ophthalmol Clin North Am. 2002;  15 473-478, vii
    PubMedGoogle Scholar
  • 42 Madreperla S A. Choroidal hemangioma treated with photodynamic therapy using verteporfin.  Arch Ophthalmol. 2001;  119 1606-1610
    PubMedGoogle Scholar
  • 43 Mang T, Allison R, Hewson G, Snider W, Moskowitz R. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer.  Cancer J Sci Am. 1998;  4 378-384
    PubMedGoogle Scholar
  • 44 Miller J, Walsh A, Kramer M, Hasan T, Michaud N, Flotte T. et al . Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin.  Arch Ophthalmol. 1995;  113 810-818
    PubMedGoogle Scholar
  • 45 Miller J W, Schmidt-Erfurth U, Sickenberg M, Pournaras C J, Laqua H, Barbazetto I. et al . Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.  Arch Ophthalmol. 1999;  117 1161-1173
    PubMedGoogle Scholar
  • 46 Montero J A, Ruiz-Moreno J M. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.  Br J Ophthalmol. 2003;  87 173-176
    CrossrefPubMedGoogle Scholar
  • 47 Pece A, Introini U, Bottoni F, Brancato R. Acute retinal pigment epithelial tear after photodynamic therapy.  Retina. 2001;  21 661-665
    PubMedGoogle Scholar
  • 48 Quaranta M, Mauget-Faysse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.  Am J Ophthalmol. 2002;  134 277-280
    CrossrefPubMedGoogle Scholar
  • 49 Rao P K, Thomas M A. Update on surgical removal of choroidal neovascularization.  Curr Opin Ophthalmol. 2000;  11 180-185
    CrossrefPubMedGoogle Scholar
  • 50 Reinke M, Canakis C, Husain D, Michaud N, Flotte T, Gragoudas E. et al . Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey.  Ophthalmology. 1999;  106 1915-1923
    CrossrefPubMedGoogle Scholar
  • 51 Robertson D M. Photodynamic therapy for choroidal hemangioma associated with serous retinal detachment.  Arch Ophthalmol. 2002;  120 1155-1161
    PubMedGoogle Scholar
  • 52 Rogers A H, Martidis A, Greenberg P B, Puliafito C A. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization.  Am J Ophthalmol. 2002;  134 566-576
    CrossrefPubMedGoogle Scholar
  • 53 Rogers A H, Greenberg P B, Martidis A, Puliafito C A. Photodynamic therapy of polypoidal choroidal vasculopathy.  Ophthalmic Surg Lasers Imaging. 2003;  34 60-63
    PubMedGoogle Scholar
  • 54 Schmidt-Erfurth U, Miller J W, Sickenberg M, Laqua H, Barbazetto I, Gragoudas E S. et al . Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.  Arch Ophthalmol. 1999;  117 1177-1187
    PubMedGoogle Scholar
  • 55 Schmidt-Erfurth U M, Kusserow C, Barbazetto I A, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas.  Ophthalmology. 2002;  109 1256-1266
    CrossrefPubMedGoogle Scholar
  • 56 Schmidt-Erfurth U M, Michels S, Kusserow C, Jurklies B, Augustin A J. Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results.  Ophthalmology. 2002;  109 2284-2294
    CrossrefPubMedGoogle Scholar
  • 57 Shaikh S, Ruby A J, Williams G A. Photodynamic therapy using verteporfin for choroidal neovascularization in angioid streaks.  Am J Ophthalmol. 2003;  135 1-6
    CrossrefPubMedGoogle Scholar
  • 58 Sheidow T G, Harbour J W. Photodynamic therapy for circumscribed choroidal hemangioma.  Can J Ophthalmol. 2002;  37 314-317
    PubMedGoogle Scholar
  • 59 Sickenberg M, Schmidt-Erfurth U, Miller J W, Pournaras C J, Zografos L, Piguet B. et al . A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.  Arch Ophthalmol. 2000;  118 327-336
    PubMedGoogle Scholar
  • 60 Spaide R F, Leys A, Herrmann-Delemazure B, Stalmans P, Tittl M, Yannuzzi L A. et al . Radiation-associated choroidal neovasculopathy.  Ophthalmology. 1999;  106 2254-2260
    CrossrefPubMedGoogle Scholar
  • 61 Spaide R F, Donsoff I, Lam D L, Yannuzzi L A, Jampol L M, Slakter J. et al . Treatment of polypoidal choroidal vasculopathy with photodynamic therapy.  Retina. 2002;  22 529-535
    CrossrefPubMedGoogle Scholar
  • 62 Spaide R F, Martin M L, Slakter J, Yannuzzi L A, Sorenson J, Guyer D R. et al . Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin.  Am J Ophthalmol. 2002;  134 62-68
    CrossrefPubMedGoogle Scholar
  • 63 Srivastava S K, Sternberg P. Retinal pigment epithelial tear weeks following photodynamic therapy with verteporfin for choroidal neovascularization secondary to pathologic myopia.  Retina. 2002;  22 669-671
    PubMedGoogle Scholar
  • 64 Stone T W, Sternberg P. Submacular surgery trials update.  Ophthalmol Clin North Am. 2002;  15 479-488
    PubMedGoogle Scholar
  • 65 Stur M, Ansari-Shahrezaei S. The effect of axial length on laser spot size and laser irradiance.  Arch Ophthalmol. 2001;  119 1323-1328
    PubMedGoogle Scholar
  • 66 Thomas E L, Langhofer M. Closure of experimental subretinal neovascular vessels with dihematoporphyrin ether augmented argon green laser photocoagulation.  Photochem Photobiol. 1987;  46 881-886
    PubMedGoogle Scholar
  • 67 Valmaggia C, Niederberger H, Helbig H. Photodynamic therapy for choroidal neovascularization in fundus flavimaculatus.  Retina. 2002;  22 111-113
    PubMedGoogle Scholar
  • 68 Wang L K, Kansal S, Pulido J S. Photodynamic therapy for the treatment of choroidal neovascularization secondary to rubella retinopathy.  Am J Ophthalmol. 2002;  134 790-792
    CrossrefPubMedGoogle Scholar
  • 69 Wind B E, Sobol W M. Surgical management of a long-standing subfoveal neovascular membrane secondary to ocular histoplasmosis.  Ophthalmic Surg. 1993;  24 36-39
    PubMedGoogle Scholar
  • 70 Woodburn K W, Engelman C J, Blumenkranz M S. Photodynamic therapy for choroidal neovascularization: a review.  Retina. 2002;  22 391-405; quiz 527 - 528
    PubMedGoogle Scholar
  • 71 Yannuzzi L A, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J. et al . Retinal angiomatous proliferation in age-related macular degeneration.  Retina. 2001;  21 416-434
    CrossrefPubMedGoogle Scholar

Univ.-Prof. Dr. Michael Stur

Univ.-Klinik für Augenheilkunde und Optometrie · Allgemeines Krankenhaus der Stadt Wien

Währinger Gürtel 18 - 20

1090 Wien · Österreich

Phone: + 43/1/40400-7915

Fax: + 43/1/40400-7959

Email: michael.stur@univie.ac.at

      >